-
Telmisartan: A Causal Benchmark for Cardiac Hypertrophy
2026-09-10
Telmisartan is an angiotensin II receptor antagonist that can serve as a receptor-proximal benchmark in cardiac hypertrophy experiments. This article contrasts AT1R blockade with RIP3/CaMKII biology and shows how to design assays that distinguish initiating signals from downstream remodeling.
-
Cabazitaxel Workflow for Resistant Cancer Models
2026-09-09
Cabazitaxel (XRP6258, SKU B2157) provides a practical taxane-based option for evaluating antiproliferative responses in P-glycoprotein-expressing and taxane-resistant cancer models. It is suited to controlled DMSO- or ethanol-based workflows, but is insoluble in water, and prepared solutions should be used promptly rather than stored long term.
-
ALDH2 Activation Delays Pressure-Overload Heart Failure
2026-09-08
A 2025 Experimental Cell Research study identifies ALDH2 activation as a way to extend the postnatal proliferative window of mouse cardiomyocytes and delay pressure-overload heart failure. The work positions Alda 1-based ALDH2 activation as a research strategy linking aldehyde detoxification, cardiomyocyte cell-cycle control, and cardiac remodeling, while leaving human translation and long-term regeneration unresolved.
-
Fosinopril Clinical Pharmacokinetics and Potential
2026-09-08
The 1997 review by Shionoiri and colleagues defined fosinopril’s clinical significance through its prodrug conversion, phosphinic acid-mediated ACE inhibition, and combined biliary and renal elimination of fosinoprilat. Its findings remain useful for interpreting blood pressure reduction, renal function, dialysis, hemodynamic effects, and drug-interaction evidence in hypertension research.
-
Dabigatran Etexilate: Oral Thrombin Inhibition
2026-09-07
The 2011 review by Blommel and Blommel presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States and explains how prodrug design addressed important limitations of warfarin and injectable anticoagulants. Its synthesis of pharmacology, pharmacokinetics, clinical efficacy, safety, and renal handling remains useful for interpreting thrombin inhibition mechanism studies and anticoagulant research.
-
Losartan: From AT1 Signaling to Matrix Biology
2026-09-05
Losartan is an angiotensin II receptor antagonist for dissecting AT1-driven vascular signaling, hypertension research, and cell-specific matrix remodeling. This article translates recent AGTR1 findings into a receptor-aware assay strategy that distinguishes vascular effects from tumor-microenvironment remodeling.
-
Angiotensin II: Mechanism and Research Protocols
2026-09-05
Angiotensin II is an endogenous octapeptide and potent vasopressor that activates angiotensin receptors to regulate vascular tone, aldosterone release, and inflammatory remodeling. Its defined receptor signaling and research-use protocols support hypertension mechanism studies, vascular smooth muscle cell hypertrophy research, and abdominal aortic aneurysm models.
-
Microglia, Synapses, and Alcohol-Induced Seizures
2026-09-04
The reference study identifies hippocampal microglial activation as a mechanistic link between acute alcohol exposure and increased seizure susceptibility. Its intervention-based design suggests that microglia influence both inhibitory and excitatory synapse formation in CA1, providing a framework for studying neuroimmune control of network excitability.
-
DIDS Workflows for Metastasis and Ion-Channel Studies
2026-09-04
DIDS links chloride-transport pharmacology with a practical near-death tumor-cell workflow for studying prometastatic states. This guide emphasizes formulation, dose selection, orthogonal controls, and interpretation across cancer, vascular, and TRPV1 models.
-
SAA–GOT2 Signaling in Doxorubicin Cardiotoxicity
2026-09-03
This 2025 study identifies GOT2, a mitochondrial enzyme in the malate-aspartate NADH shuttle, as a functional target of salvianolic acid A in doxorubicin-induced cardiotoxicity. Its integrated omics, biophysical, genetic, and animal-model evidence links GOT2-dependent redox metabolism with improved cardiac function, while also indicating that salvianolic acid A can preserve antitumor activity in a lung-cancer model.
-
Resiniferatoxin (RTX): TRPV1 Research
2026-09-02
Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist that produces sustained cation influx and long-lasting desensitization of TRPV1-positive sensory endings. Its selective pharmacology supports preclinical research on osteoarthritis pain, neuropathic pain, postoperative pain, neurogenic inflammation, and context-dependent immune signaling.
-
Cyanidin Chloride: From Redox Mechanism to Translation
2026-09-02
A mechanistic, identity-aware guide to using Cyanidin Chloride in oxidative stress research, with practical assay strategy, interpretation of psoriasis-model evidence, and a disciplined path from reactive oxygen species scavenging to translational endpoints.
-
TMEM16F in Kupffer Cells Protects Against Listeria
2026-09-02
The reference study identifies Kupffer cell-expressed TMEM16F as a key determinant of host protection during Listeria monocytogenes infection, shifting the focus from lymphocytes to liver-resident macrophages. Its data connect calcium-activated lipid scrambling and plasma-membrane repair with control of liver inflammation, tissue injury, and metabolic disruption.
-
Alda 1 for ALDH2 Activation in Cardiac Research
2026-09-01
Alda 1 provides a practical way to test how ALDH2 activation links aldehyde detoxification with cardiomyocyte survival and proliferation. This guide translates recent pressure-overload findings into assay-ready workflows for cardiac ischemia research, ALDH2 variant comparisons, and carefully bounded radiation studies.
-
How GCG Disrupts SARS-CoV-2 N Condensation
2026-08-31
The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic feature of viral biology and shows that (-)-gallocatechin gallate disrupts this process. Its integrated sequence, biochemical, infection-associated, and replication analyses support viral condensates as a potential antiviral target, while also defining important limits for translation.